Project Grant R01CA308197
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $534K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Roxbury, MA 02118, USA
Similar Awards
- Federal Project Grant Award Summary Boston Children's Hospital received a $679,604 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2025 through July 31, 2030. The grant supports fundamental research investigating pathways involved in melanoma initiation and formation using zebrafish genetic models. Research activities include studying melanocyte-specific expression of oncogenic mutations, identifying and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $607,249 under the Cancer Cause and Prevention Research program (CFDA 93.393) effective May 1, 2026, through April 30, 2031. The award supports research investigating the role of the transcription factor MAFG (MAF Basic Leucine Zipper G) in melanocyte transformation and melanoma development. The research addresses non-genetic...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Boston University a $230,762 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to support research and training initiatives in cancer therapy delivery systems. The grant, awarded July 1, 2025, with completion scheduled for February 29, 2028, funds the development of disulfated polyamidosaccharide nanoparticles as a targeted chemotherapeutic delivery system. The research addresses the critical...
- Federal Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $510,431 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2025 through June 30, 2030. This award supports fundamental research investigating the mechanisms of metastatic recurrence and therapeutic resistance in melanoma, with particular emphasis on understanding how aging influences tumor dormancy and the microenvironment. The research examines Wnt signaling...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Grant Award Summary The National Cancer Institute awarded Harvard Medical School a $237,023 Project Grant under the Cancer Biology Research program (CFDA 93.396) beginning March 13, 2026, with completion targeted for February 28, 2029. This award supports the development and application of high-throughput tools designed to track the fate of prematurely terminated transcripts in cancer cells, specifically focusing on alternative polyadenylation (APA) events that drive oncogenic mechanisms...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts Institute of Technology (MIT) a project grant of $133,955 on August 7, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support cancer research training and investigation through July 31, 2027. The grant funds research examining how cancer cachexia—progressive wasting of skeletal muscle, fat, and other tissues observed in pancreatic ductal adenocarcinoma (PDAC) patients—influences...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $659,201 Project Grant effective June 1, 2026 through May 30, 2031 under the Cancer Treatment Research program (CFDA 93.395). This award supports research investigating the integrated stress response (ISR) in glioblastoma (GBM) pathogenesis and therapeutic response. The project focuses on understanding how the interplay between phosphorylated eukaryotic translation initiation factor 2A...
- Federal Project Grant Award Summary The National Cancer Institute awarded $1.22M to the University of Massachusetts Boston under its Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, through July 31, 2028. This project grant supports fundamental research to advance understanding of extracellular vesicles (EVs)—cell-derived, membrane-bound structures that carry biomolecules and serve as circulating biomarkers for disease diagnosis and therapeutic delivery. The research...
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $682,495 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on melanoma pathogenesis and treatment. The award, effective June 1, 2026, through May 31, 2031, supports a five-year investigation into the SPOP-BRAF-mTORC1 signaling axis in melanoma development. The research focuses on understanding how...